RNA-seq analysis of nintedanib effects on interstitial pneumonia in preoperative NSCLC patients
- 5 February 2026
- journal article
- Published by Elsevier in Respiratory Medicine
- Vol. 253, 108704
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Molecular imaging in experimental pulmonary fibrosis reveals that nintedanib unexpectedly modulates CCR2 immune cell infiltrationEBioMedicine, 2024
- Amphiregulin in lung diseases: A reviewMedicine, 2024
- Omentin roles in physiology and pathophysiology: an up-to-date comprehensive reviewArchives of Physiology and Biochemistry, 2023
- Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)Pulmonary Pharmacology & Therapeutics, 2023
- Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumoniaRespiratory Investigation, 2019
- Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ONThe Lancet Respiratory Medicine, 2019
- Intelectin contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic dermatitisMucosal Immunology, 2017
- Lung cancer risk among patients with combined pulmonary fibrosis and emphysemaRespiratory Medicine, 2014
- Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis aloneRespirology, 2013
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)JNCI: Journal of the National Cancer Institute, 2005